Gold Mining News – Lifestyle
Home
Sample Page
Author:
HUTCHMED (China) Limited
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
April 8, 2026
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 26, 2026
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
March 22, 2026